Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study
Authors' conclusion
The incidence of ICI-IA identified in claims data is similar to that reported in observational studies; however, few patients are treated with a DMARD or are referred to rheumatologist. There was no difference in overall survival between ICI-treated patients with and without ICI-IA.
Study context
- Population
- Medicare 5% sample patients initiating immune checkpoint inhibitor (ICIs) for lung cancer, melanoma or renal/urothelial cancer
- Exposure
- ICI-treated patients with vs without ICI-IA
- Outcome
- Incidence of ICI-IA
Methodological detailsadministrative claims (Medicare 5% sample), landmark analysis, time-varying Cox proportional hazards model
- Administrative claims (Medicare 5% sample)
- Landmark analysis
- Time-varying Cox proportional hazards model
Main finding
As reported in the abstract
ICI-IA
7.2
CI 6.1–8.4 · per 100 patient years
Observational data: associations, not effects.
Further findings
- Time from ICI initiation to first ICI-IA diagnosis
- 124 · Median · IQR 56–252 · days
Received care from a rheumatologist (patients with ICI-IA)
- Only 24 (16%) received care from a rheumatologist
Prescribed a DMARD (patients with ICI-IA)
- 24 (16%) were prescribed a DMARD
- 46% by a rheumatologist
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study. Rheumatology (Oxford). Published 18 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →